1229441-17-1

Basic information

• Product Name: 5-(cyclopropylmethoxy)-3'-(5-(3-(3,5-dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-[1,1'-biphenyl]-3-carboxylic acid
• Synonyms: 5-(cyclopropylmethoxy)-3'-(5-(3-(3,5-dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-[1,1'-biphenyl]-3-carboxylic acid
• CAS NO: 1229441-17-1
• Molecular Weight: 594.454
• Mol File: 1229441-17-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-(cyclopropylmethoxy)-3'-(5-(3-(3,5-dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-[1,1'-biphenyl]-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(cyclopropylmethoxy)-3'-(5-(3-(3,5-dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-[1,1'-biphenyl]-3-carboxylic acid(1229441-17-1)
• EPA Substance Registry System: 5-(cyclopropylmethoxy)-3'-(5-(3-(3,5-dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-[1,1'-biphenyl]-3-carboxylic acid(1229441-17-1)

Safety Data

• Hazardous Substances Data: 1229441-17-1(Hazardous Substances Data)

Upstream product

• 1229442-28-7 4-amino-6-(3-bromophenyl)-2-ethylpyridazin-3(2H)-one 
• 1229442-63-0 ethyl 3-bromo-5-(cyclopropylmethoxy)benzoate 
• 870673-35-1 3-bromo-5-hydroxybenzoic acid ethyl ester 
• 1229442-27-6 5-acetyl-4-amino-6-(3-bromophenyl)-2-ethylpyridazin-3(2H)-one 
• 140472-69-1 3-bromo-5-hydroxy-benzoic acid 
• 42237-85-4 3-amino-5-bromobenzoic acid 
• 1229442-26-5 4-(3-bromophenyl)-6-ethyl-3-methylisoxazolo[3,4-d]pyridazin-7(6H)-one 
• 6307-83-1 3-bromo-5-nitro-benzoic acid 
• 1229442-25-4 4-(3-bromophenyl)-3-methylisoxazolo[3,4-d]pyridazin-7(6H)-one 
• 1229442-24-3 ethyl 4-(3-bromobenzoyl)-5-methylisoxazole-3-carboxylate 
• 152706-83-7 1-(3-bromophenyl)butane-1,3-dione 
• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 121-92-6 3-nitrobenzoic acid 
• 1229442-29-8 1-(6-(3-bromophenyl)-2-ethyl-3-oxo-2,3-dihydropyridazin-4-yl)-3-(3,5-dichloropyridin-4-yl)urea 

Downstream Products

• 1229441-19-3 5-(cyclopropylmethoxy)-3'-(5-(3-(3,5-dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-N-(2-(piperidin-1-yl)ethyl)-[1,1'-biphenyl]-3-carboxamide 

Relevant articles and documents

Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships

Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs. In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD. Here we describe our efforts to discover novel, highly potent inhaled inhibitors of PDE4. Through structure based design, with the inclusion of a variety of functional groups and physicochemical profiles in order to occupy the solvent-filled pocket of the PDE4 enzyme, we modified the structure of our oral PDE4 inhibitors to reach compounds down to picomolar enzymatic potencies while at the same time tackling successfully an uncovered selectivity issue with the adenosine receptors. In vitro potencies were demonstrated in a rat lung neutrophilia model by administration of a suspension with a Penn-Century MicroSprayer Aerosolizer.